Collegium Pharmaceutical Inc (COLL)

[floblu14]

Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference
August 30, 2022 at 8:00 AM EDT
STOUGHTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster presentations highlighting data regarding its product portfolio will be presented at the Annual PAINWeek National Conference, taking place September 6-9, 2022 in Las Vegas, NV.

“Collegium is excited to support 11 posters regarding our meaningfully differentiated product portfolio that will be presented at PAINWeek 2022 National Conference,” said Thomas Smith, MD, EVP and Chief Medical Officer of Collegium. “We welcome opportunities to share clinical and real-world data with the medical community as part of our commitment to make a positive difference in the lives of people living with serious medical conditions.”

Poster Presentations:

Poster Title: Budget Impact Analysis of Xtampza® ER (oxycodone extended-release) for the Treatment of Chronic Pain from a Managed Care Perspective
Authors: Alan G. White, Todd Kunkel, Mancia Ko, Hongjue Wang

Poster Title: Treatment Effects of Celecoxib Oral Solution in Migraine with Aura and Without Aura: Post-HOC Analysis of Results from Two Randomized, Double-Blind Placebo-Controlled Trials
Authors: Stewart Tepper, Daniel Serrano, Mancia Ko, Todd Kunkel, Richard B. Lipton

Poster Title: Consistency of Response to Liquid Celecoxib in Adults with Migraine: Post HOC Analysis of Results from Two Randomized, Placebo-Controlled Studies
Authors: Daniel Serrano, Stewart Pepper, Mancia Ko, Todd Kunkel, Richard B. Lipton

Poster Title: Efficacy of Celecoxib Oral Solution in Adults with and Without Baseline Nausea: Post-HOC Analysis of Results from Two Randomized, Double-Blind Placebo-Controlled Trials in the Acute Treatment of Migraine
Authors: Richard B. Lipton, Daniel Serrano, Mancia Ko, Todd Kunkel, Stewart Pepper

Poster Title: Celecoxib Oral Solution in the Acute Treatment of Migraine: Pooled Efficacy and Safety Results From 2 Randomized Placebo-controlled Trials
Authors: Stewart Pepper, Harvey Kushner, Mancia Ko, Todd Kunkel, Richard B. Lipton

Poster Title: Impact of Celecoxib Oral Solution on Symptomatic Improvements in the Acute Treatment of Migraine
Authors: Stewart Pepper, Harvey Kushner, Mancia Ko, Todd Kunkel

Poster Title: Prescription Opioid Nonmedical Use via Oral Manipulation: An Under-Recognized Risk
Authors: Jody L. Green, Taryn Dailey-Govoni, Suzanna K. Vosburg

Poster Title: Association between per capita prescribing and abuse of tapentadol and other opioids among individuals entering treatment for opioid use disorders
Authors: Stevan Geoffrey Severtson, Annika M. Czizik, Matthew Ellis, Joshua C. Black, Janetta Iwanicki, Richard C. Dart

Poster Title: Non-Medical Use of XTAMPZA ER: Motivation, Methods, and Perceptions of Tampering
Authors: Joshua C. Black, Karilynn M. Rockhill, S. Geoff Severtson, Richard C. Dart

Poster Title: Cross-sectional Study of Tampering in an Abuse-Deterrent Formulation of an Extended-Release Opioid in a Treatment Center Population
Authors: Jennifer Jewell, Joshua Black, Matthew Ellis, Heather Olsen, Janetta Iwanicki, Richard Dart

Poster Title: Differences in the severity of medical outcomes of exposures reported to poison centers involving XTAMPZA® ER and other opioid analgesics
Authors: Stevan Geoffrey Severtson, Joshua C. Black, Janetta Iwanicki, Richard C. Dart

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-11-poster-presentations-painweek-2022

Refer to PAIN WEEK -
https://www.painweek.org/